Agnos Therapeutics

Agnos Therapeutics develops AGN-001, an off-the-shelf cell therapy designed to treat inherited retinal diseases (IRDs) by delivering healthy proteins to rescue sight across multiple genetic mutations. The company's approach targets the more than 99% of inherited blindness patients who currently lack approved treatment options by using a gene-agnostic cell therapy that aims to restore function to surviving photoreceptors rather than replacing lost cells.